Appendix Table C64. Clinical outcomes (outcomes part A), ACEI/ARB plus aldosterone antagonist versus ACEI/ARB plus placebo trial

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **All-cause Mortality**  **n/N (%)** | | **Cardiovascular Mortality**  **n/N (%)** | | **Myocardial Infarction,**  **Any n/N (%)** | | **Myocardial Infarction,**  **Fatal, n/N (%)** | | **Myocardial infarction,**  **Nonfatal, n/N (%)** | | **Stroke, Any**  **n/N (%)** | |
| **ACEI/ARB+ AA** | **ACEI/ARB + PBO** | **ACEI/ARB + AA** | **ACEI/ARB + PBO** | **ACEI/ARB + AA** | **ACEI/ARB + PBO** | **ACEI/ARB + AA** | **ACEI/ARB + PBO** | **ACEI/ARB + AA** | **ACEI/ARB + PBO** | **ACEI/ARB + AA** | **ACEI/ARB + PBO** |
| van der Meiracker, 200656 | 0/29 | 2/30 (6.7%) |  |  |  |  | 0/29 | 2/30 (6.7%) |  |  |  |  |

ACEI/ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker; AA = aldosterone antagonist; PBO = placebo